PARP inhibitors are drugs that inhibit PARP enzymes and constitute the only targeted therapies used in pancreatic cancer indicated for tumors with germline BRCA1/BRCA2 mutations [53]. This evidence concerns the gene BRCA2 and familial pancreatic carcinoma.